Skip to contentI
Integra Lifesciences Holdings Corp
I
IARTIntegra Lifesciences Holdings Corp Q4 2019 · 10-K
Revenue$395.13M$395.13M+3.1% vs Q4 2018 Net Income$15.32M$15.32M−39.1% vs Q4 2018 EPS Diluted$0.18$0.18−37.9% vs Q4 2018 Gross Profit$245,665,000+3.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Integra Lifesciences Holdings Corp · CIK 917520 · Engraved from SEC EDGAR
derived
Operating Cash Flowderived$89,184,000+108.9% Free Cash Flowderived$66,990,000+294.0% Margins · derivedGross margin62.2%+0.4 pt vs Q4 2018
Operating margin9.1%+0.2 pt vs Q4 2018
Net margin3.9%−2.7 pt vs Q4 2018
ended Dec 31, 2019 · filed Feb 21, 2020 · 52 d after period end